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Introduction
The clear association between high fibrinogen concentrations and the risk of cardiovascular disease is of increasing practical relevance as well as scientific interest. The relation was first reported in preliminary results from the Northwick Park Heart Study in 1980' and later confirmed in its main findings.2 Numerous other prospective studies have almost without exception confirmed a strong and independent effect of raised plasma fibrinogen on both the onset and the progression of ischaemic heart disease (IHD), stroke and lower extremity arterial disease. 3 4 The strength of the association is similar to that of cholesterol or blood pressure. Thus, men with plasma fibrinogen concentrations in the upper third of its distribution experience between 2.0 and 2.5 times the incidence of IHD compared with those with values in the lower third; the Framingham study has also confirmed this relation in women. 5 In one of the studies with data on stroke as well as IHD,6 the relation of fibrinogen with the incidence of the former was, if anything, stronger than for blood pressure, thus exemplifying the likely importance of fibrinogen, bearing in mind the predominance of blood pressure as a risk factor for stroke. Fibrinogen is strongly associated with mortality (mostly from cardiovascular causes) in patients with intermittent claudication7 and also with venous thrombosis. There is by now fairly extensive evidence from randomised trials that fat, carbohydrate and fibre intake do not influence fibrinogen concentration in humans, at any rate in the short term. The only possible exception is fish oil which may lower the fibrinogen concentration, although the evidence is equivocal.'2 Second, smoking is a particularly important determinant of the fibrinogen concentration, probably exerting its effect on IHD through the haemostatic system rather than through lipids. The time course for the return of fibrinogen to non-smoking concentrations'3 is similar to that for the decline among ex-smokers in the risk of IHD itself, with an obvious initial fall (in both fibrinogen concentration and risk of IHD) starting quite soon, which does not, however, reach non-smoking levels for several years thereafter. It is possible that residual lung damage resulting in increased cytokine production stimulates fibrinogen synthesis and thus raised plasma concentrations for a considerable time after smoking has been discontinued. Emphasis on the importance of smoking as a determinant of fibrinogen should not, however, obscure the fact that high concentrations also predict IHD in non-smokers.'4 Third, while infection causes many changes in addition to a rise in fibrinogen, it is certainly possible that the latter may partly explain the association of infection with increased IHD and stroke mortality.'5 If this is indeed the case, there may be large and significant implications for reducing the incidence of these conditions.
As fibrinogen is an acute phase protein, the high concentrations associated with IHD and with its risk factors could at least in part be a response to underlying vessel wall disease, which has many of the characteristics of an inflammatory process. It is, however, a mistake to assume that this detracts from the value of measuring fibrinogen for clinical purposes or from the pathogenetic importance of raised concentrations. First 200 healthy subjects of different ages of each sex. At present, a "normal" value of, say, 2.7 g/l from one laboratory may be quite a low value from another. Once plasma has been separated, fibrinogen concentrations remain fairly stable for up to about 24 hours but may deteriorate unpredictably thereafter so that beyond this limit standard corrections to allow for delay between taking blood and analysis of fresh samples are not possible. Plasma can, however, be stored at low temperature for analysis later on. As with any other risk factor-for example, cholesterol or blood pressure, more than one measurement of fibrinogen is necessary to determine an individual's true or habitual concentration and, because of the acute phase response, samples should not be taken during or too soon after intercurrent infections, etc.
The topic of fibrinogen and arterial disease is at the same kind of interface between research and service that characterised the discussion of cholesterol 20 
